2026-01-02 - Analysis Report
Okay, here's a breakdown of the Salesforce (CRM) stock analysis, incorporating the provided data:

**Salesforce Inc. Overview:** Salesforce is a global leader in cloud-based software, providing customer relationship management (CRM) solutions.

**1. Return Rate Comparison & Alpha/Beta Analysis:**

*   **Cumulative Return:**
    *   CRM: -6.74%
    *   VOO (S&P 500): 91.40%
*   **Divergence:** -111.8 (Relative Divergence: 8.0)

    *   **Analysis:** CRM has significantly underperformed the S&P 500. The divergence is quite large, indicating a substantial difference in returns. The relative divergence suggests that this underperformance is near the minimum historically.

*   **Alpha, Beta Analysis:**

    | Year       | CAGR    | MDD   | Alpha   | Beta | Cap(B) |
    |------------|---------|-------|---------|------|--------|
    | 2016-2018  | 13.0%   | 99.2% | 9.0%    | 1.4  | 130.4  |
    | 2017-2019  | 15.0%   | 86.5% | -2.0%   | 1.4  | 154.8  |
    | 2018-2020  | 9.0%    | 86.5% | -11.0%  | 1.1  | 211.8  |
    | 2019-2021  | 33.0%   | 78.7% | -10.0%  | 1.1  | 241.9  |
    | 2020-2022  | -73.0%  | 100.0%| -71.0%  | 1.2  | 126.2  |
    | 2021-2023  | -42.0%  | 100.0%| -43.0%  | 1.4  | 250.5  |
    | 2022-2024  | -37.0%  | 100.0%| -56.0%  | 1.4  | 318.3  |
    | 2023-2025  | 10.0%   | 99.9% | -52.0%  | 1.2  | 252.2  |

    *   **CAGR:** The Compound Annual Growth Rate has fluctuated significantly.
    *   **MDD:** The Maximum Drawdown has been substantial, especially in recent years.
    *   **Alpha:** Alpha is consistently negative in recent periods, meaning CRM has underperformed its benchmark on a risk-adjusted basis.
    *   **Beta:** Beta is generally around 1.1 to 1.4, suggesting that CRM's price is more volatile than the market.

**2. Recent Stock Price Fluctuations:**

*   Close: 264.91
*   Last-market: {'price': 264.91, 'previousClose': 265.92, 'change': -0.38}
*   5-day SMA: 265.68
*   20-day SMA: 259.90
*   60-day SMA: 249.06

    *   **Analysis:** The stock price is slightly below the 5-day SMA but above the 20-day and 60-day SMAs, suggesting a short-term pullback after a recent upward trend. The negative change in the last market indicates a very slight downward fluctuation.

**3. RSI, PPO, and Relative Divergence:**

*   Market Risk Indicator (MRI): 0.9 (Medium Investment Recommended)
*   RSI: 51.39
*   PPO: 0.11
*   Hybrid Signal: cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   Recent (20 days) relative divergence change: 1.4 (+)
*   Expected Return (%): 0.0

    *   **Analysis:**
        *   **MRI:** The MRI suggests a medium investment recommendation.
        *   **RSI:** The RSI is near the middle (50), indicating neutral momentum.
        *   **PPO:** The PPO is slightly positive, suggesting a slight upward trend.
        *   **Hybrid Signal:** Leans towards a 'Buy' recommendation.
        *   **Relative Divergence Change:** The recent increase suggests a short-term upward movement.
        *   **Expected Return:** The 0% expected return is concerning, meaning there are no expectations of outperformance relative to the S&P 500 for at least 2 years.

**4. Recent News & Significant Events:**

*   **Positive Sentiment:** Several articles suggest that Salesforce's earnings might be improving and the stock could be undervalued ("Salesforce Stock Now 27% Cheaper, Time To Buy").
*   **Partnerships:** The partnership with USDOT is a positive sign for growth and innovation.
*   **Analyst Activity:** Articles mention analyst price targets and forecasts, indicating continued monitoring and valuation of the stock.
*   **Seeking Alpha's Stance:** The Seeking Alpha article expresses a bullish sentiment ("Salesforce: Strong Performance, Why I Am Buying More").
*   **Overall:** The news leans positive, suggesting a potential turnaround in sentiment.

**4-2. Analyst Opinions:**

*   Target Price (avg/high/low): 330.06 / 475.00 / 223.00

    *   **Analysis:** The average target price is significantly higher than the current price, indicating potential upside according to analysts.  However, the range between the high and low targets is very wide, suggesting uncertainty.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue  |
|------------|------|----------|
| 2025-12-04 | 2.20 | 10.26 B$ |
| 2025-09-04 | 1.97 | 10.24 B$ |
| 2025-05-29 | 1.61 | 9.83 B$ |
| 2024-12-04 | 1.60 | 9.44 B$ |
| 2025-12-04 | 1.60 | 9.44 B$ |

*   **Analysis:**
    *   EPS and revenue have been generally increasing.
    *   Recent EPS has significantly increased.

**6. Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue      | Profit Margin |
|---------------|--------------|---------------|
| 2025-10-31   | $10.26B     | 78.02%       |
| 2025-07-31   | $10.24B     | 78.10%       |
| 2025-04-30   | $9.83B      | 76.96%       |
| 2025-01-31   | $9.99B      | 77.81%       |
| 2024-10-31   | $9.44B      | 77.71%       |

Capital and Profitability:

| Quarter      | Equity      | ROE      |
|---------------|-------------|----------|
| 2025-10-31   | $60.02B    | 3.48%   |
| 2025-07-31   | $61.33B    | 3.08%   |
| 2025-04-30   | $60.67B    | 2.54%   |
| 2025-01-31   | $61.17B    | 2.79%   |
| 2024-10-31   | $58.52B    | 2.61%   |

*   **Analysis:**
    *   **Revenue:** Consistent growth in revenue over the past few quarters.
    *   **Profit Margin:** Strong and relatively stable profit margins.
    *   **Equity:** Slight fluctuations in equity.
    *   **ROE:** ROE is increasing, suggesting improved profitability relative to equity.

**7. Comprehensive Analysis (Summary):**

*   **Underperformance:** CRM has significantly underperformed the S&P 500 historically.
*   **Negative Alpha:**  Indicates underperformance relative to its benchmark.
*   **Recent Improvement:** Recent earnings and revenue figures are promising.
*   **Positive News Sentiment:** Recent news articles and analyst opinions lean towards a more positive outlook.
*   **Analyst Target Prices:** Analysts have a higher target price than the current price.
*   **Neutral Momentum:** The RSI suggests neutral momentum.
*   **Medium Risk:** The MRI suggests a medium level of investment risk.
*   **Financials:**  Revenue and profit margins look very healthy.
*   **Warning:**  The 0% Expected Return relative to S&P500 implies long term concerns.

**Overall Recommendation:**

While CRM has struggled recently and shows significant underperformance compared to the S&P 500, recent financial data and news sentiment suggest a potential turnaround.  The increasing revenue, strong profit margins, and positive analyst outlook are encouraging. However, the negative alpha and zero expected return, alongside a relatively high beta, should give investors pause.

**Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice.  Conduct thorough research and consult with a financial advisor before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.